Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Damora Therapeutics, Inc.NASDAQ: DMRA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 1.33M shares rose 0.4% year over year, behind the +9.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +9.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
1.33M+0.0% QoQ
Last fiscal yearDec 2025
1.33M+14.7% YoY
LTMMar 2026
1.33M+9.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+14.7%——
3-year CAGR+9.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
1.33M USD
Year-over-year change
+14.7%
4-year CAGR
+7.1%

Weighted Avg Shares vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's LTM Mar 2026 weighted avg shares of 1.33M shares is the lowest of the 9 companies compared; the peer median is 48.66M shares.
  • Its year-over-year change of +9.5% is the 3rd highest of 7, against a peer median of +2.5%.
  • Over three fiscal years its annual growth of +9.3% compares with a peer median of +7.2%.
DMRA Competitors Peer median
Weighted Avg Shares for DMRA and competitors
Company Period LTM YoY 3-year CAGR
GERNGeron CorporationLTM Mar 2026667.45M +1.6%+20.5%
GMABGenmab A/SLTM Jun 2026614.84M —-1.7%
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
KROSKeros Therapeutics, Inc.LTM Mar 202638.92M +1.7%+13.8%
IRONDisc Medicine, Inc.LTM Sep 202637.84M +13.4%+223.8%
COAGHemab Therapeutics Holdings, Inc. Common StockFY202527.44M ——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
DMRADamora Therapeutics, Inc.LTM Mar 20261.33M +9.5%+9.3%
Peer median (excluding DMRA) 48.66M+2.5%+7.2%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue441K490K830K181K0
Gross Profit(441K)(490K)(830K)(181K)0
Gross Margin—————
Research & Development38.49M48.21M23.77M6.4M201.19M
Selling, General & Admin13.3M12.51M11.86M10.32M9.69M
Operating Expenses51.79M60.72M35.63M16.72M210.87M
Depreciation & Amortization441K490K830K181K34K
EBITDA(51.31M)(61.13M)(37.52M)(21.22M)(209.76M)
EBITDA Margin—————
Operating Income(52.23M)(61.21M)(36.46M)(16.9M)(210.87M)
Operating Margin—————
Interest Income156K722K1.69M844K1.17M
Interest Expense00000
Other Income / Expenses475K(417K)(1.89M)(4.5M)1.08M
Income Before Tax(51.75M)(61.62M)(38.35M)(21.4M)(209.79M)
Pre-Tax Margin—————
Income Tax Expense00041K50K
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Net Margin—————
EPS (Basic)(51.22)(60.63)(36.08)(18.53)(158.13)
EPS (Diluted)(51.22)(60.63)(36.08)(18.53)(158.13)
Weighted Avg Shares1.01M1.02M1.06M1.16M1.33M
Weighted Avg Shares (Diluted)1.01M1.02M1.06M1.16M1.33M

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.